Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis

Summary

The primary objective of this study is to evaluate the effect of 12 weeks of treatment with once daily administration of AQX-1125 compared to placebo on change from baseline in Total Lesion Symptom Score in subjects with mild to moderate atopic dermatitis

Timeline

Start

2014-12

Primary completion

2015-11

Completion

2015-12

Outcome

Missed primary endpoint

registry analysis (superiority or other test); AQX-1125 vs Placebo; p = 0.636; Mean Difference (Final Values) -0.02 (95% CI -1.30 to 1.25); ANCOVA NCT02324972 ↗

Drugs

Indications